PharmaVentures http://www.pharmatelevision.com A PharmaTelevision Channel en PharmaVentures Ltd 2009 PharmaVentures Ltd enquiries@pharmaventures.com http://images.pharmaventures.com/ptv/tbr.jpg http://www.pharmatelevision.com/ Businessno PharmaVentures LtdWelcome to the July 2007 edition of the PharmaVentures Business Review. In the Business Report we investigate the trends surrounding upfront payments in licensing deals. In the Month in Review, we review the industry's key deals during June 2007 and their likely impact on the companies involved as well as on the market sector. In Face-to-Face, Fintan Walton talks to Tim Zeppenfeld, Business Development Manager, Gene Bridges about life as a self-funded and profitable emerging biotechnology company in Germany. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.Welcome to the July 2007 edition of the PharmaVentures Business Review. In the Business Report we investigate the trends surrounding upfront payments in licensing deals. In the Month in Review, we review the industry's key deals during June 2007 and their likely impact on the companies involved as well as on the market sector. In Face-to-Face, Fintan Walton talks to Tim Zeppenfeld, Business Development Manager, Gene Bridges about life as a self-funded and profitable emerging biotechnology company in Germany. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.Welcome to the July 2007 edition of the PharmaVentures Business Review. In the Business Report we investigate the trends surrounding upfront payments in licensing deals. In the Month in Review, we review the industry's key deals during June 2007 and their likely impact on the companies involved as well as on the market sector. In Face-to-Face, Fintan Walton talks to Tim Zeppenfeld, Business Development Manager, Gene Bridges about life as a self-funded and profitable emerging biotechnology company in Germany. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool. http://media.pharmatelevision.com/15.m4v Sun, 01 Jul 2007 00:00:00 GMTBusinessNo PharmaVentures LtdIn the fifth PharmaVentures Business Review of 2007, we take a look at the generics sector of the pharmaceutical industry. In the Business Report, we investigate the trends in deal making for the generics sector and discuss the types of deals that make it unique – compared with the rest of the pharmaceutical industry. In the Month in Review, we review the industry's key deals during April 2007 and their likely impact on the companies involved as well as on the market sector. In Face-to-Face, Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrated specialty pharmaceutical company. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.In the fifth PharmaVentures Business Review of 2007, we take a look at the generics sector of the pharmaceutical industry. In the Business Report, we investigate the trends in deal making for the generics sector and discuss the types of deals that make it unique – compared with the rest of the pharmaceutical industry. In the Month in Review, we review the industry's key deals during April 2007 and their likely impact on the companies involved as well as on the market sector. In Face-to-Face, Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrated specialty pharmaceutical company. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.In the fifth PharmaVentures Business Review of 2007, we take a look at the generics sector of the pharmaceutical industry. In the Business Report, we investigate the trends in deal making for the generics sector and discuss the types of deals that make it unique – compared with the rest of the pharmaceutical industry. In the Month in Review, we review the industry's key deals during April 2007 and their likely impact on the companies involved as well as on the market sector. In Face-to-Face, Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrated specialty pharmaceutical company. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool. http://media.pharmatelevision.com/14.m4v Tue, 01 May 2007 00:00:00 GMTBusinessNo PharmaVentures LtdIn the fourth PharmaVentures Business Review of 2007, we focus on the cardiovascular sector. In the Business Report, we take a look at the current status of the cardiovascular therapy market and investigate the trends in deal making throughout the last decade for this major segment of the pharmaceutical industry. In the Month in Review, we review the industry's key deals during March 2007 and their likely impact on the companies involved as well as the market sector. In Face-to-Face, Fintan Walton talks to Damian Marron, Vice President, Corporate Development, NicOx, about the company’s achievements to date and its ambitious plans for the future. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.In the fourth PharmaVentures Business Review of 2007, we focus on the cardiovascular sector. In the Business Report, we take a look at the current status of the cardiovascular therapy market and investigate the trends in deal making throughout the last decade for this major segment of the pharmaceutical industry. In the Month in Review, we review the industry's key deals during March 2007 and their likely impact on the companies involved as well as the market sector. In Face-to-Face, Fintan Walton talks to Damian Marron, Vice President, Corporate Development, NicOx, about the company’s achievements to date and its ambitious plans for the future. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.In the fourth PharmaVentures Business Review of 2007, we focus on the cardiovascular sector. In the Business Report, we take a look at the current status of the cardiovascular therapy market and investigate the trends in deal making throughout the last decade for this major segment of the pharmaceutical industry. In the Month in Review, we review the industry's key deals during March 2007 and their likely impact on the companies involved as well as the market sector. In Face-to-Face, Fintan Walton talks to Damian Marron, Vice President, Corporate Development, NicOx, about the company’s achievements to date and its ambitious plans for the future. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool. http://media.pharmatelevision.com/12.m4v Sun, 01 Apr 2007 00:00:00 GMTBusinessNo PharmaVentures LtdIn the third PharmaVentures Business Review of 2007, we focus our attention on the drug discovery sector. In the Business Report, we take a look at some of the key trends in drug discovery deal making across the past five years and review the key stages of the drug discovery process as well as the key technologies that have been boosting deal making in this important sector of the pharmaceutical market. In the Month in Review, we review the industry's key deals during February 2007 and their likley impact on the companies involved and the market sector. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.In the third PharmaVentures Business Review of 2007, we focus our attention on the drug discovery sector. In the Business Report, we take a look at some of the key trends in drug discovery deal making across the past five years and review the key stages of the drug discovery process as well as the key technologies that have been boosting deal making in this important sector of the pharmaceutical market. In the Month in Review, we review the industry's key deals during February 2007 and their likley impact on the companies involved and the market sector. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.In the third PharmaVentures Business Review of 2007, we focus our attention on the drug discovery sector. In the Business Report, we take a look at some of the key trends in drug discovery deal making across the past five years and review the key stages of the drug discovery process as well as the key technologies that have been boosting deal making in this important sector of the pharmaceutical market. In the Month in Review, we review the industry's key deals during February 2007 and their likley impact on the companies involved and the market sector. To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool. http://media.pharmatelevision.com/11.m4v Thu, 01 Mar 2007 00:00:00 GMTBusinessNo PharmaVentures LtdThe Tenth Edition of PharmaVentures Business ReviewThe Tenth Edition of PharmaVentures Business ReviewThe Tenth Edition of PharmaVentures Business Review http://media.pharmatelevision.com/10.m4v Thu, 01 Feb 2007 00:00:00 GMTBusinessNo PharmaVentures LtdIn The Business Report we investigate some of the trends in deal making for 2006, putting them into the context of deal making across the last 10 years of industry activity. We also review biotech IPO performance in 2006 and discuss some of the key industry drivers over the year.In The Business Report we investigate some of the trends in deal making for 2006, putting them into the context of deal making across the last 10 years of industry activity. We also review biotech IPO performance in 2006 and discuss some of the key industry drivers over the year.In The Business Report we investigate some of the trends in deal making for 2006, putting them into the context of deal making across the last 10 years of industry activity. We also review biotech IPO performance in 2006 and discuss some of the key industry drivers over the year. http://media.pharmatelevision.com/119.m4v Mon, 01 Jan 2007 00:00:00 GMTBusinessNo PharmaVentures LtdIn this month’s business report, we take an overview of the technology transfer process and provide a summary of the various steps involved in taking an idea from university laboratories to the market-place. We also examine some of the trends that PharmaVentures' business analysts have been observing in technology transfer deals over the past decade, looking at both product- and technology-based deals, and asking which academic centres have been most active in licensing their technology.In this month’s business report, we take an overview of the technology transfer process and provide a summary of the various steps involved in taking an idea from university laboratories to the market-place. We also examine some of the trends that PharmaVentures' business analysts have been observing in technology transfer deals over the past decade, looking at both product- and technology-based deals, and asking which academic centres have been most active in licensing their technology.In this month’s business report, we take an overview of the technology transfer process and provide a summary of the various steps involved in taking an idea from university laboratories to the market-place. We also examine some of the trends that PharmaVentures' business analysts have been observing in technology transfer deals over the past decade, looking at both product- and technology-based deals, and asking which academic centres have been most active in licensing their technology. http://media.pharmatelevision.com/120.m4v Fri, 01 Dec 2006 00:00:00 GMTBusinessNo PharmaVentures LtdIn this month's business report, we take a look at strategic alliance management and examine the factors that that can make the difference between a successful alliance and a terminated deal. We highlight the different types of risk and the conflict inherent in the alliance management process, and discuss the practical approaches that can be taken in order to avoid alliance failure. These include using alliance risk diagnostics, establishing the 'rules of engagement', specialist problem-solving techniques and calculating an 'alliance scorecard'.In this month's business report, we take a look at strategic alliance management and examine the factors that that can make the difference between a successful alliance and a terminated deal. We highlight the different types of risk and the conflict inherent in the alliance management process, and discuss the practical approaches that can be taken in order to avoid alliance failure. These include using alliance risk diagnostics, establishing the 'rules of engagement', specialist problem-solving techniques and calculating an 'alliance scorecard'.In this month's business report, we take a look at strategic alliance management and examine the factors that that can make the difference between a successful alliance and a terminated deal. We highlight the different types of risk and the conflict inherent in the alliance management process, and discuss the practical approaches that can be taken in order to avoid alliance failure. These include using alliance risk diagnostics, establishing the 'rules of engagement', specialist problem-solving techniques and calculating an 'alliance scorecard'. http://media.pharmatelevision.com/121.m4v Wed, 01 Nov 2006 00:00:00 GMTBusinessNo PharmaVentures LtdIn this month's Business Report we discuss the current climate for the early-stage funding of biotech companies in the US. We explore some of the options open to biotech entrepreneurs in order to secure the crucial finances necessary to start a successful business. We assess the trends in early-stage funding awarded by the US National Institutes of Health SBIR and STTR grant programmes and take a closer look at how early-stage funding from Venture Capital sources has changed over the last decade.In this month's Business Report we discuss the current climate for the early-stage funding of biotech companies in the US. We explore some of the options open to biotech entrepreneurs in order to secure the crucial finances necessary to start a successful business. We assess the trends in early-stage funding awarded by the US National Institutes of Health SBIR and STTR grant programmes and take a closer look at how early-stage funding from Venture Capital sources has changed over the last decade.In this month's Business Report we discuss the current climate for the early-stage funding of biotech companies in the US. We explore some of the options open to biotech entrepreneurs in order to secure the crucial finances necessary to start a successful business. We assess the trends in early-stage funding awarded by the US National Institutes of Health SBIR and STTR grant programmes and take a closer look at how early-stage funding from Venture Capital sources has changed over the last decade. http://media.pharmatelevision.com/122.m4v Sun, 01 Oct 2006 00:00:00 GMTBusinessNo PharmaVentures LtdThis month's business report looks at trends in deal making within the oncology sector. Using data from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, we take a look at changes in the number and type of oncology deals that have been signed since 2000. We then focus on licensing deals and investigate the trends in the types of company, product and phase of development and identify which are the most prolific deal making companies in this sector. We also discuss the relative attrition rates for products in this field of therapeutic medicine.This month's business report looks at trends in deal making within the oncology sector. Using data from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, we take a look at changes in the number and type of oncology deals that have been signed since 2000. We then focus on licensing deals and investigate the trends in the types of company, product and phase of development and identify which are the most prolific deal making companies in this sector. We also discuss the relative attrition rates for products in this field of therapeutic medicine.This month's business report looks at trends in deal making within the oncology sector. Using data from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, we take a look at changes in the number and type of oncology deals that have been signed since 2000. We then focus on licensing deals and investigate the trends in the types of company, product and phase of development and identify which are the most prolific deal making companies in this sector. We also discuss the relative attrition rates for products in this field of therapeutic medicine. http://media.pharmatelevision.com/123.m4v Fri, 01 Sep 2006 00:00:00 GMTBusinessNo PharmaVentures LtdIn this month's Business Report, we assess the valuation methodologies used in deal transactions for assets such as drugs in development, whole pipelines or business assets. We use data sourced from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, to look briefly at some of the trends in shifting deal values for licensing deals and for products in different therapeutic areas.In this month's Business Report, we assess the valuation methodologies used in deal transactions for assets such as drugs in development, whole pipelines or business assets. We use data sourced from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, to look briefly at some of the trends in shifting deal values for licensing deals and for products in different therapeutic areas.In this month's Business Report, we assess the valuation methodologies used in deal transactions for assets such as drugs in development, whole pipelines or business assets. We use data sourced from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, to look briefly at some of the trends in shifting deal values for licensing deals and for products in different therapeutic areas. http://media.pharmatelevision.com/124.m4v Tue, 01 Aug 2006 00:00:00 GMTBusinessNo PharmaVentures LtdIn the Business Report this month, we investigate the trends in deal making for products that have reached Phase III or later in the development process. Using data sourced from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, we assess both the overall numbers and types of deals that have been made over the last 6 years, as well as taking a closer look at the most frequent late-stage deal types: marketing, licensing and manufacturing.In the Business Report this month, we investigate the trends in deal making for products that have reached Phase III or later in the development process. Using data sourced from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, we assess both the overall numbers and types of deals that have been made over the last 6 years, as well as taking a closer look at the most frequent late-stage deal types: marketing, licensing and manufacturing.In the Business Report this month, we investigate the trends in deal making for products that have reached Phase III or later in the development process. Using data sourced from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, we assess both the overall numbers and types of deals that have been made over the last 6 years, as well as taking a closer look at the most frequent late-stage deal types: marketing, licensing and manufacturing. http://media.pharmatelevision.com/125.m4v Sat, 01 Jul 2006 00:00:00 GMTBusinessNo PharmaVentures LtdIn this month's Business Report, we focus on some of the trends that business analysts at PharmaVentures have been observing in the biotech IPO landscape. We consider both long- and short-term trends in IPOs across the globe and take a closer look at some of the biotech companies that have gone public this year in order to gain an important insight into the status of the biotech IPO market-place as it stands, halfway through 2006.In this month's Business Report, we focus on some of the trends that business analysts at PharmaVentures have been observing in the biotech IPO landscape. We consider both long- and short-term trends in IPOs across the globe and take a closer look at some of the biotech companies that have gone public this year in order to gain an important insight into the status of the biotech IPO market-place as it stands, halfway through 2006.In this month's Business Report, we focus on some of the trends that business analysts at PharmaVentures have been observing in the biotech IPO landscape. We consider both long- and short-term trends in IPOs across the globe and take a closer look at some of the biotech companies that have gone public this year in order to gain an important insight into the status of the biotech IPO market-place as it stands, halfway through 2006. http://media.pharmatelevision.com/126.m4v Thu, 01 Jun 2006 00:00:00 GMTBusinessNo